New drug MRX-2843 tested in patients with advanced cancers
NCT ID NCT03510104
First seen Jan 11, 2026 · Last updated May 17, 2026 · Updated 21 times
Summary
This early-phase study tested a new drug called MRX-2843 in 42 adults with advanced or metastatic solid tumors that had not responded to prior treatments. The main goal was to check the drug's safety and find the best dose. Researchers monitored side effects and how the drug moved through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University
Atlanta, Georgia, 30322, United States
-
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27514, United States
Conditions
Explore the condition pages connected to this study.